Replies to post #17 on Autolus Therapeutics Plc (AUTL)

[jondoeuk]

Both lead assets (AUTO1 and AUTO3) have shown promising data to date, with best-in-class potential. I know they are now looking to partner the latter, and for the former, AUTO1 could see approval in 2022 (aALL).

Other assets, including AUTO4/5 (both in T-cell lymphoma's), AUTO6NG (in select GD2+ solid tumours), and AUTO7 (mCRPC) are also promising.

So I have a long-term position.